Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer

Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer

Submitted by admin on November 13, 2022 - 7:06pm
Source: 
BioSpace
News Tags: 
Cue Biopharma
CUE-101
head and neck cancer
Headline: 
Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer
snippet: 

Early clinical data from a combination of Cue Biopharma's interleukin 2 (IL-2)-based biologic, CUE-101 and Merck's Keytruda shows the treatment is effective in patients with recurrent/metastatic HPV16+ head and neck cancer.

Do Not Allow Advertisers to Use My Personal information